Mira Pharmaceuticals Announces Selection Of Neuropathic Pain As Indication For Ketamir-2 And Submits Pre-IND Meeting Request To FDA
Portfolio Pulse from Benzinga Newsdesk
Mira Pharmaceuticals has chosen neuropathic pain as the primary indication for its ketamine analog, Ketamir-2, and has submitted a pre-IND meeting request to the FDA. The meeting is expected in October 2024, with human trials planned for early 2025.
September 10, 2024 | 8:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mira Pharmaceuticals has selected neuropathic pain as the indication for Ketamir-2 and submitted a pre-IND meeting request to the FDA. This is a key step towards starting human trials in early 2025.
The selection of neuropathic pain as an indication and the submission of a pre-IND meeting request are significant steps in the drug development process. This progress could positively impact MIRA's stock as it moves closer to human trials, indicating potential future revenue streams.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100